NYSE · ATR
Healthcare · Medical - Instruments & Supplies
$125.45
Down-$0.71 (-0.57%)
Updated Sep 23, 2026, 10:29 PM
SID Score
4.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ATR closed at $125.45 after 20 trading sessions, down 6.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $124.72 | $125.7999 | $123.825 | $125.45 | 417.72K |
| Sep 21, 2026 | $124.84 | $125.98 | $123.32 | $123.40 | 424.45K |
| Sep 18, 2026 | $125.49 | $125.77 | $124.41 | $124.44 | 821.26K |
| Sep 17, 2026 | $125.66 | $126.22 | $124.55 | $125.50 | 551.46K |
| Sep 16, 2026 | $124.84 | $126.25 | $123.2001 | $124.71 | 461.61K |
| Sep 15, 2026 | $124.85 | $124.86 | $123.405 | $124.68 | 474.73K |
| Sep 14, 2026 | $125.28 | $126.21 | $124.00 | $124.91 | 423.16K |
| Sep 11, 2026 | $124.85 | $125.595 | $123.06 | $124.84 | 491.93K |
| Sep 10, 2026 | $122.05 | $123.12 | $120.74 | $123.05 | 435.09K |
| Sep 9, 2026 | $123.97 | $123.97 | $121.09 | $122.11 | 383.03K |
| Sep 8, 2026 | $126.20 | $126.99 | $124.25 | $124.34 | 362.19K |
| Sep 4, 2026 | $127.53 | $128.4699 | $126.525 | $127.41 | 323.99K |
| Sep 3, 2026 | $130.65 | $130.65 | $126.99 | $128.31 | 339.99K |
| Sep 2, 2026 | $131.27 | $132.26 | $129.69 | $130.33 | 472.48K |
| Sep 1, 2026 | $131.65 | $132.07 | $130.7825 | $130.92 | 418.16K |
| Aug 31, 2026 | $132.21 | $132.44 | $130.83 | $131.62 | 389.24K |
| Aug 28, 2026 | $133.55 | $133.655 | $132.04 | $132.99 | 325.43K |
| Aug 27, 2026 | $133.78 | $134.69 | $132.26 | $132.86 | 295.69K |
| Aug 26, 2026 | $135.00 | $136.64 | $134.435 | $135.24 | 281.38K |
| Aug 25, 2026 | $135.59 | $135.59 | $133.22 | $134.72 | 280.92K |
The latest Smart Investors Daily articles mentioning ATR.
ATR research
Company profile and research snapshot.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (49% of sales) and the United States (32%), Aptar aims to increase its presence in Asia (11%) and Latin America (8%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Wells Fargo | Overweight | — |
| May 4, 2026 | Wells Fargo | Overweight | — |
| Mar 20, 2026 | Wells Fargo | Overweight | — |
| Jan 6, 2026 | Wells Fargo | Equal-Weight | — |
| Nov 3, 2025 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
AptarGroup, Inc. (ATR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsGael Touya - CEO,...
Yahoo · Sep 14, 2026
CRYSTAL LAKE, Ill., September 14, 2026--Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery
Benzinga · Sep 14, 2026
Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelinesAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection
SeekingAlpha · Sep 9, 2026
AptarGroup, Inc. (ATR) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 12:45 PM EDTCompany ParticipantsGael Touya - CEO, President &...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATR.
